FDA approves Cytalux for ovarian cancer imaging

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved Cytalux, a fluorescent imaging agent that binds to cancer cells and allows physicians to identify cancerous lesions during ovarian cancer surgery. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login